Ambroxol sustained release

Drug Profile

Ambroxol sustained release

Alternative Names: MUCOSOLVAN; NA872ET

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Teijin Pharma
  • Developer Boehringer Ingelheim; Teijin Pharma
  • Class Aniline compounds; Antibronchitics; Cyclohexylamines; Expectorants; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Cough

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cough(In volunteers) in Brazil (PO, Lozenge)
  • 02 Feb 2015 Registered for Cough in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top